AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

GLMD · NASDAQ · Biotechnology

Galmed Pharmaceuticals (GLMD)

Develops Aramchol candidates and CG-100 for colorectal surgery.

$4.06

Pre-market+0.02 (+0.50%)

At close$4.04(+2.93%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

1.03M ADS (1 ADS = 25 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing

The share count is from the company's Dec 2022 annual report; nothing newer is on file here.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
683 Capital Management, LLCInstitution	—3.80% of class, as filed	—	13G/Afiled Feb 13, 2020 ↗
BVF Inc.Strategic	—8.40% of class, as filed	—	13G/Afiled Feb 12, 2021 ↗
Chaim HurvitzInsider	—7.30% of class, as filed	—	13G/Afiled Jan 26, 2018 ↗
Investors LLCStrategic	—1.40% of class, as filed	—	13G/Afiled Jan 27, 2022 ↗
Wilmot B. HarkeyInsider	—1.20% of class, as filed	—	13G/Afiled Feb 14, 2022 ↗
Yarom Medical Research Ltd.Strategic	—16.00% of class, as filed	—	13G/Afiled Feb 12, 2021 ↗

13D/13G — an ownership statement filed at 5% or more

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

No 13D/G filer at 5% or more on record.

Insider tradesForm 4

Latest trades

Nothing filed in the last 12 months.

CongressHouse and Senate disclosures

Not reported.